Show simple item record

dc.contributor.authorLázaro, Ariadna
dc.contributor.authorBalcells, Cristina
dc.contributor.authorQuirante, Josefina
dc.contributor.authorBadia, Josefa
dc.contributor.authorBaldomà, Laura
dc.contributor.authorWard, Jas S.
dc.contributor.authorRissanen, Kari
dc.contributor.authorFont-Bardia, Mercè
dc.contributor.authorRodriguez, Laura
dc.contributor.authorCrespo, Margarita
dc.contributor.authorCascante, Marta
dc.date.accessioned2020-01-08T09:21:25Z
dc.date.available2020-01-08T09:21:25Z
dc.date.issued2020
dc.identifier.citationLázaro, A., Balcells, C., Quirante, J., Badia, J., Baldomà, L., Ward, J. S., Rissanen, K., Font-Bardia, M., Rodriguez, L., Crespo, M., & Cascante, M. (2020). Luminescent PtII and PtIV Platinacycles with Anticancer Activity Against Multiplatinum‐Resistant Metastatic CRC and CRPC Cell Models. <i>Chemistry : A European Journal</i>, <i>26</i>(9), 1947-1952. <a href="https://doi.org/10.1002/chem.201905325" target="_blank">https://doi.org/10.1002/chem.201905325</a>
dc.identifier.otherCONVID_33978759
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/67158
dc.description.abstractAbstract: Platinum‐based chemotherapy persists to be the only effective therapeutic option against a wide variety of tumours. Nevertheless, the acquisition of platinum resistance is utterly common, ultimately cornering conventional platinum drugs to only palliative in many patients. Thus, encountering alternatives that are both effective and non‐cross‐resistant is urgent. In this work, we report the synthesis, reduction studies and luminescent properties of a series of cyclometallated (C,N,N’) PtIV compounds derived from amine‐imine ligands, and their remarkable efficacy at the high nanomolar range and complete lack of cross‐resistance, as an intrinsic property of the platinacycle, against multiplatinum‐resistant colorectal cancer (CRC) and castration‐resistant prostate cancer (CRPC) metastatic cell lines generated for this work. We have also determined that the compounds are effective and selective for a broader cancer panel, including breast and lung cancer. Additionally, selected compounds have been further evaluated, finding a shift in their antiproliferative mechanism towards more cytotoxic and less cytostatic than cisplatin against cancer cells, being also able to oxidize cysteine residues and inhibit topoisomerase II, thereby holding great promise as future improved alternatives to conventional platinum drugs.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherWiley-VCH Verlag
dc.relation.ispartofseriesChemistry : A European Journal
dc.rightsIn Copyright
dc.titleLuminescent PtII and PtIV Platinacycles with Anticancer Activity Against Multiplatinum‐Resistant Metastatic CRC and CRPC Cell Models
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202001081083
dc.contributor.laitosKemian laitosfi
dc.contributor.laitosDepartment of Chemistryen
dc.contributor.oppiaineOrgaaninen kemiafi
dc.contributor.oppiaineOrganic Chemistryen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.description.reviewstatuspeerReviewed
dc.format.pagerange1947-1952
dc.relation.issn0947-6539
dc.relation.numberinseries9
dc.relation.volume26
dc.type.versionacceptedVersion
dc.rights.copyright© 2020 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim
dc.rights.accesslevelopenAccessfi
dc.subject.ysobiologinen aktiivisuus
dc.subject.ysolääkehoito
dc.subject.ysosyöpätaudit
dc.subject.ysoresistenssi
dc.subject.ysoluminesenssi
dc.subject.ysoplatina
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p24582
jyx.subject.urihttp://www.yso.fi/onto/yso/p10851
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
jyx.subject.urihttp://www.yso.fi/onto/yso/p16107
jyx.subject.urihttp://www.yso.fi/onto/yso/p1646
jyx.subject.urihttp://www.yso.fi/onto/yso/p12535
dc.rights.urlhttp://rightsstatements.org/page/InC/1.0/?language=en
dc.relation.doi10.1002/chem.201905325
jyx.fundinginformationThis work was supported by the Ministerio de Economia y Competitividad (Projects CTQ-2015-65040-P, CTQ2015-65707C2-1/FEDER,AEI/FEDER CTQ2016-76120-P, CTQ2017-90802-REDT,SAF2017-89673-R and SAF2015-70270-REDT), Instituto de Salud Carlos III and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD CB17/04/00023), Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) –Generalitat deCatalunya (2017SGR-1033). M.Cascante acknowledges the support received through the prize “ICREA Academia” for excellence in research, funded by ICREA foundation –Generalitat de Catalunya.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

In Copyright
Except where otherwise noted, this item's license is described as In Copyright